Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

MLA

Prasil, Petr, et al. “Comparison of Adverse Reactions of Spiramycin versus Pyrimethamine/Sulfadiazine Treatment of Toxoplasmosis in Pregnancy: Is Spiramycin Really the Drug of Choice for Unproven Infection of the Fetus?” Journal of Maternal-Fetal & Neonatal Medicine, vol. 36, no. 1, Jan. 2023, pp. 1–6. EBSCOhost, https://doi.org/10.1080/14767058.2023.2215377.

APA

Prasil, P., Sleha, R., Kacerovsky, M., & Bostik, P. (2023). Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus? Journal of Maternal-Fetal & Neonatal Medicine, 36(1), 1–6. https://doi.org/10.1080/14767058.2023.2215377

Chicago

Prasil, Petr, Radek Sleha, Marian Kacerovsky, and Pavel Bostik. 2023. “Comparison of Adverse Reactions of Spiramycin versus Pyrimethamine/Sulfadiazine Treatment of Toxoplasmosis in Pregnancy: Is Spiramycin Really the Drug of Choice for Unproven Infection of the Fetus?” Journal of Maternal-Fetal & Neonatal Medicine 36 (1): 1–6. doi:10.1080/14767058.2023.2215377.